12 July 2018 - - Hertfordshire, England-based global pharmaceutical company Mylan N.V. (NASDAQ, TASE: MYL) has launched the rivastigmine transdermal system, a generic version of the Exelon patch, in the US, the company said.
Launch of the Mylan patch follows receipt of final approval from the US FDA for its abbreviated new drug application for the product.
Rivastigmine transdermal system, in dosings of 4.6 mg/24 hrs, 9.5 mg/24 hrs, and 13.3 mg/24 hrs, is indicated for the treatment of dementia associated with mild, moderate, and severe Alzheimer's disease and the treatment of mild to moderate dementia associated with Parkinson's disease.
Mylan president Rajiv Malik said, "The launch of generic Exelon Patch is another example of the investment Mylan is continuing to make into products that are difficult to develop and manufacture, particularly in transdermal drug-delivery systems."
Mylan offers a broad and diverse portfolio, with more than 7,500 marketed products that include prescription generic and brand-name medicines, and consumer healthcare products.
The company also has healthcare services to help patients access products and adhere to medication regimens to help promote better health outcomes. The company markets products in more than 165 countries and territories.